EGFR mutation has been demonstrated to be the strongest predictor for the benefits of these EGFR-TKIs [3], which have shown to be superior to chemotherapy in terms of overall response rate (ORR), progression-free survival (PFS), and quality of life in untreated patients with EGFR mutation-positive NSCLC [2, 4–11]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.